<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000100020</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20220001000020</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Dapsona como opción terapéutica en el tratamiento de acné fulminans por isotretinoína]]></article-title>
<article-title xml:lang="en"><![CDATA[Dapsone as a therapeutic option in the treatment of acne fulminans by isotretinoin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Minardi]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Universitario del Hospital Italiano Farmacia Ambulatoria. Hospital Italiano de Buenos Aires Depto. Farmacología y Toxicología]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>1</numero>
<fpage>103</fpage>
<lpage>104</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000100020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Acné fulminans es una afección poco frecuente caracterizada por la rápida aparición de lesiones nodulares e inflamatorias en pecho, espalda, cuello y hombros que progresan a úlceras necróticas con secreción purulenta, costras sanguíneas, cicatrices hipertróficas, y que además, puede asociar sintomatología sistémica. Afecta principalmente a pacientes adolescentes de sexo masculino, su etiopatogenia no está completamente elucidada y mecanismos de origen inmunológico, genético, infeccioso u hormonal han sido propuestos como posible causa. Existen también algunos casos relacionados al uso de isotretinoína debido probablemente a la fragilidad del folículo piloso que esta droga produce y que exacerba las reacciones de hipersensibilidad (tipo III y IV) tras un extenso contacto con P. acnes. Sin embargo, la ausencia de pautas clínicas claras o información basada en evidencia sobre la clasificación y tratamiento, complejiza el manejo de esta patología especialmente cuando es inducida por isotretinoína. A continuación se describe el caso de un adolescente con diagnóstico de acné fulminante inducido por isotretinoína sin síntomas sistémicos, que fue tratado con dapsona.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary Acne fulminans is a rare condition characterized by an abrupt onset of nodular and inflammatory lesions on the chest, back, neck and shoulders that rapidly progress to necrotic ulcers with purulent discharge, blood crusts and hypertrophic scars and it may or may not be associated with systemic symptoms. It affects mainly young male patients and the etiopathogenesis is not completely elucidated and immunological, genetic, infectious or hormonal mechanisms have been proposed. There are also a few acne fulminans's clinical cases related to the use of oral isotretinoin probably due to the fragility of the pilosebaceous epithelium induced by this drug, that exacerbate hypersensitivity reactions (type III and IV) after a extensive contact with P. acnes. However, the limited evidence-based information and the lack of clear guidelines on its etiology, classification and treatment complicate the clinical management of the disease, especially when it's induced by isotretinoin. Here is described the case of a young male patient with isotretinoin-induced acne fulminans without systemic symptoms, which was treated with dapsone.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Acné fulminans]]></kwd>
<kwd lng="es"><![CDATA[isotretinoína]]></kwd>
<kwd lng="es"><![CDATA[dapsona]]></kwd>
<kwd lng="en"><![CDATA[Acne fulminans]]></kwd>
<kwd lng="en"><![CDATA[isotretinoin]]></kwd>
<kwd lng="en"><![CDATA[dapsone]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giavedoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acne fulminans successfully treated with cyclosporine and isotretinoin]]></article-title>
<source><![CDATA[Journal of the American Academy of Dermatology]]></source>
<year>2014</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e38-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaba]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Jarmuda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Czarnecka-Operacz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silny]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acne fulminans: explosive systemic form of acne]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2011</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>501-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greywal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zaenglein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chernoff]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rosso]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based recommendations for the management of acne fulminans and its variants]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2017</year>
<volume>77</volume>
<page-range>109-17</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalbarczyk]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ciupinska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complications during treatment with Roaccutane, acne fulminans 2001]]></article-title>
<source><![CDATA[Dermatol Klin]]></source>
<year>2001</year>
<volume>3</volume>
<numero>Suppl. 1</numero>
<issue>Suppl. 1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Colville]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acne conglobata with septicemia]]></article-title>
<source><![CDATA[Arch Dermatol]]></source>
<year>1959</year>
<volume>79</volume>
<page-range>361-3</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seukeran]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Cunliffe]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The treatment of acne fulminans: a review of 25 cases]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>1999</year>
<volume>141</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>307-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schram]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenbach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acne fulminans]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Zeichner]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Acneiform eruptions in dermatology: a differential diagnosis]]></source>
<year>2014</year>
<edition>1st</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer-Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chivot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poussées inflammatoires et aggravations d'acné sous isotrétinoïne orale]]></article-title>
<source><![CDATA[Ann Dermatol Venereol]]></source>
<year>2001</year>
<volume>128</volume>
<page-range>224-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lages]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Bona]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[FVM]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[AKL]]></given-names>
</name>
<name>
<surname><![CDATA[Campelo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acne fulminans successfully treated with prednisone and dapsone]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2012</year>
<volume>87</volume>
<page-range>612-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vinod]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Arun]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dutta]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapsone hypersensitivity syndrome: A rare life threatening complication of dapsone therapy]]></article-title>
<source><![CDATA[Journal of Pharmacology &amp; Pharmacotherapeutics]]></source>
<year>2013</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>158-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
